Publications by authors named "Hanano Mamada"

Claim this Profile
E
Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors' Self-Citation Rate in Japan and the United States.
Hanano Mamada, Anju Murayama, Sae Kamamoto, Yudai Kaneda, Makoto Yoshida

Arthritis Care Res (Hoboken)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.
Makoto Kosaka, Akihiko Ozaki, Yudai Kaneda, Hiroaki Saito, Erika Yamashita, Hanano Mamada

Cost Eff Resour Alloc· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financial Relationships Between Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and 2019.
Anju Murayama, Hanano Mamada, Haruki Shigeta, Takamichi Yoshinaga, Hiroaki Saito

J Clin Rheumatol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019.
Hanano Mamada, Anju Murayama, Akihiko Ozaki, Takanao Hashimoto, Hiroaki Saito

Medicine (Baltimore)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019.
Anju Murayama, Momoko Hoshi, Hiroaki Saito, Sae Kamamoto, Manato Tanaka, Hanano Mamada

Respiration· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019.
Anju Murayama, Sae Kamamoto, Hiroaki Saito, Kohki Yamada, Divya Bhandari, Hanano Mamada

Int J Environ Res Public Health· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan.
Takanao Hashimoto, Anju Murayama, Hanano Mamada, Hiroaki Saito, Tetsuya Tanimoto

Clin Microbiol Infect· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis